KOD News and Press, Kodiak Sciences Inc From 10/05/21

Baker Brothers’ 13F portfolio value decreased from $23.07B to $22.77B this quarter. The InVitae stake was reduced this quarter while increasing Apellis Pharma and Heron Therapeutics. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almo...

Kodiak Sciences Announces New Long-Term Performance Incentive Plan <p><b><i> Pay for Performance: Program Aligns Incentives to Significant Value Creation through Share Price Milestones of $200 to $800 per Share </i></b></p> PR Newswire ...

Kodiak Sciences to Present at the Morgan Stanley 19th Annual Global Healthcare Conference PR Newswire PALO ALTO, Calif. , Aug. 31, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commer...

Kodiak Sciences Announces Second Quarter 2021 Financial Results and Recent Business Highlights PR Newswire PALO ALTO, Calif. , Aug. 9, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and co...

AMRX,APD,AVYA,BALY,BHVN,BLUE,BNTX,CEVA,CRNC,DISH,EBIX,ELAN,ENR,EPZM,GOLD,GTES,KOD,RDNT,SGMS,SWAV,SYNH,TGNA,TSN,TTD,USFD,VTRS,VTR For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Monday's open

Kodiak Sciences (NASDAQ: KOD) is a mid-cap biotech business building a drug portfolio focused on retina therapeutics. The Palo Alto, California based company has an approximate market cap of $4.5 billion. Kodiak launched its IPO in 2018, and it has been heads down pushing its pipeli...

Today, we look at a biotech firm who is developing a portfolio of retina therapeutics built on the company’s antibody biopolymer conjugate platform. Kodiak has late-stage drug candidate targeting wet age-related macular degeneration, diabetic macular edema, retinal vein occlusi...

Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...

Regenxbio (RGNX) has an internal gene therapy pipeline and also earns licensing revenue from partners using their IP. The internal pipeline and partner programs have progressed substantially. Regenxbio has a cash-rich balance sheet with $650 million. In Q3, Regenixbio will pro...

Kodiak Sciences (KOD) has extended the intra-day losses yesterday with a ~10.6% drop in the pre-market.In a regulatory filing, the company has announced that ~14.0M shares will be sold by the selling stockholders from time to time.The offer includes ~150.0K shares of its common stoc...